

# SA Xinyi Glass HK\$8.08 - BUY



We appreciate your support in the Asiamoney Brokers Poll. Please click here to use our voting matrix for this year.

Looking at global opportunities

In line 1H17 with better 2H likely; new capacity plans ahead XYG's 1H17 core profit growth of 25% was in-line, with revenue/GPM boosted by soaring float glass ASP YoY despite some cost hike that was a drag on auto/construction GPM. We reiterate our view of stable float demand/supply due to still-growing property and limited new capacity, with a more constructive 2H17 amid seasonal strength and GPM expansion on lower costs. Management is also looking for capacity expansion, more aggressive on float and also some on auto. This, plus any further stabilising float glass dynamics and cost reduction, are potential catalysts. Given an undemanding valuation, we maintain BUY with TP unchanged at HK\$9.60.

## In-line 1H17

XYG's 1H core profit was HK\$1,681m (after excluding FX loss), up 24.8% YoY and in line with CL. Revenue (+13.5% YoY) was largely in line, with a slight miss in float glass revenue (due to volume) that was offset by construction glass sales. Overall GPM was largely in line too amid an ASP-driven float glass GPM surge (30.1%, +7.8ppt YoY) despite a miss in auto/construction glass GPM on higher costs. Lower-than-expected opex/depreciation and higher associate income offset lower other income and higher interest.

## Stable float glass, expecting better 2H

We reiterate our view of stable demand/supply dynamics for float glass in 2017 due to still-growing property sales/new starts GFA and limited new capacity YTD. We also see a more constructive 2H17, with seasonally stronger demand that supports prices, and falling soda ash/natural gas prices by end-1Q17 plus lower-cost Malaysia plant likely boosting the GPM.

## New expansion plans

Given favourable float glass performance globally, XYG plans to increase its float glass capacity by 50% from the 2017 level, with no geographical limitation. Besides, XYG plans to add auto glass capacity including OEM, as well as aftermarket with new overseas capacity to reduce the impact of antidumping. We have not yet incorporated these plans into our model but these are likely positive earnings drivers; especially, overseas float glass plants in the US and Malaysia would bring cost advantages.

## **Maintain BUY**

We fine-tune our 17/18/19CL core profit to factor in slightly higher revenue offset by slightly lower GPM. Our TP is unchanged at HK\$9.60; it is based on a blended PE/PB approach. Retain BUY on the undemanding valuation of 8x 18CL PE/6% dividend yield potential.

## **Financials**

Year to 31 December	15A	16A	17CL	18CL	19CL
Revenue (HK\$m)	11,460	12,848	14,336	15,292	16,060
Adjusted net profit (HK\$m)	1,734	3,055	3,745	4,161	4,652
Adjusted EPS (HK¢)	43.0	76.5	94.4	103.7	116.0
CL/consensus (9) (EPS%)	-	-	103	103	113
Adj EPS growth (% YoY)	51.7	77.8	23.4	9.9	11.8
Adjusted PE (x)	18.8	10.6	8.6	7.8	7.0
Dividend yield (%)	3.3	5.0	5.6	6.2	7.0
ROE (%)	16.9	24.8	26.5	25.7	25.2
Net debt/equity (%)	37.2	37.0	37.8	24.3	11.9
Source: CLSA					

## Timothy Lee, CFA

timothy.lee@clsa.com +852 2600 8461

Alec So, CFA +852 2600 8742

1 August 2017

## China Materials

Reuters 0868.HK Bloomberg 868 HK Priced on 31 July 2017 HS CEI @ 10,827.8 12M hi/lo HK\$8.39/5.69 **12M price target** HK\$9.60

±% potential	+19%
Shares in issue Free float (est.)	3,891.8m 43.9%
Market cap	US\$4,138m
3M average daily	volume

HK\$69.2m (US\$8.9m)

Foreign s'holding 52.0%

**Major shareholders** Lee Yin Yee 22.0% Tung Ching Sai 9.8%

## Stock performance (%)



www.clsa.com

Find CLSA research on Bloomberg, Thomson Reuters, Factset and CapitaIIQ - and profit from our evalu@tor proprietary database at clsa.com

## For important disclosures please refer to page 13.



In-line 1H17 XYG's 1H17 core profit was calculated to be HK\$1,681m after excluding FX Largely inline 1H17, on revenue, GPM and profit loss, up 24.8% YoY and in line with CL. Reported profit of HK\$1,636m was just marginally 1.4% below Bloomberg. Revenue (+13.5% YoY) was largely in line, with a slight miss in float glass revenue (due to volume) offset by better than expected construction glass sales. Overall GPM was also largely in line at 36.4% (+1.7ppt YoY) amid an ASP-driven float glass GPM surge (30.1%, +7.8ppt YoY) despite some miss in auto/construction glass GPM on higher cost. Besides, lower than expected opex/depreciation and higher associates income (from XYS's beat) offset lower other income and higher interest. **Key highlights:** Float glass ASP soared Revenue was up 13.5% YoY to HK\$6,677m, marginally below our forecast YoY despite volume being by 0.6%. In particular: likely lower than our forecast, offset by better Revenue from float glass segment surged 35.3% YoY, 2.4% below our construction glass sales forecast which we believe was due to slightly lower than expected sales volume. Meanwhile, strong YoY growth was mainly driven by the significant increase in float glass market prices since 2H16 which stayed high in 1H17, resulting in significant YoY increase in ASP. Revenue from auto glass was down 6.0% YoY, in line with our forecast. 0 The YoY decline was due to a change in accounting treatment as the company started to take out the rebate from revenue in 2H16, which resulted in lower revenue but at the same time lower expenses as well. Besides, FX movements and also spin-off of Xinyi Automobile Glass Hong Kong (8328.HK) also resulted in some revenue decline. Revenue from construction glass was down 2.7% YoY which we believe was partly dragged down by RMB depreciation, but 3.4% above us. Overall GPM was 36.4%, up 1.7ppt YoY, marginally lower than us by **Overall GPM was largely**  $\geq$ in line, boosted by float 0.5ppt. In particular: glass despite dragged by higher cost in 1Q17 GPM for float glass was 30.1% (up 7.8ppt YoY), in line with our 0 estimate, thanks to significantly higher ASP YoY, (but slightly lower than 31.2% in 2H16 given the higher soda ash/natural gas costs in 1Q17). GPM for auto glass was 47.8% (down 0.9ppt YoY), 1.1ppt below our estimate. GPM for construction glass was 37.5% (down 1.5ppt YoY), 0.7ppt below. These were also lower than 2H16's 49.3%/40.6%, respectively, also due to higher soda ash/natural gas costs in 1Q17. Opex was up 5.3% YoY to HK\$893m, 4.3% below our forecast, Lower than expected opex/depreciation and suggesting better efficiency. Depreciation expense was up 1.4% YoY, higher associates income 7.8% below our estimate. offset lower other income and higher interest  $\geq$ Other revenue was up 36.0% YoY to HK\$141m, but 18.7% below our forecast.

Interest expense was up 21.2% YoY to HK\$73m, 60.8% above our estimate amid higher debt, but is likely to fall in 2H after all CBs are exercised.

2



- The share of profit of associates was up 17.8% YoY to HK\$368m, 24.5% above our estimate due to better-than-expected 1H17 results of Xinyi Solar (29.5% owned by XYG).
- Reported profit was HK\$1,636m, up 19.5% YoY. Excluding FX loss of HK\$45m, core profit is calculated to be HK\$1,681m, up 24.8% YoY and in line with our forecast.
- An interim dividend of HK 20 cents was declared, implying a payout ratio of 48% (1H16: 48%).

XYG – 1H17 results highlights						
HKD m	1H16	2H16	1H17	YoY growth	1H17CL	Forecast vs actual
Sales	5,885	6,963	6,677	13.5%	6,718	(0.6%)
COGS (excl depr)	(3,455)	(3,937)	(3,853)	11.5%	(3,815)	1.0%
Operating expenses (ex D&A)	(848)	(944)	(893)	5.3%	(934)	(4.3%)
Opex %	14.4%	13.6%	13.4%	(7.2%)	13.9%	(3.7%)
Core EBITDA	1,582	2,082	1,931	22.0%	1,969	(1.9%)
Depreciation	(389)	(408)	(395)	1.4%	(428)	(7.8%)
Core EBITA	1,193	1,674	1,536	28.7%	1,541	(0.3%)
Amortisation	(15)	(15)	(27)	79.7%	(15)	84.2%
Core EBIT	1,178	1,659	1,509	28.1%	1,526	(1.1%)
Ebit Margin	20.0%	23.8%	22.6%		22.7%	
Other revenue (ex interest exp)	104	238	141	36.0%	174	(18.7%)
Interest Income	16	35	23	46.3%	15	52.2%
Interest Expense	(60)	(67)	(73)	21.2%	(45)	60.8%
Net Interest Expense	(44)	(33)	(50)	12.0%	(30)	65.2%
Share of Associate Profit	312	250	368	17.8%	295	24.5%
Profit Before Tax	1,550	2,115	1,968	27.0%	1,965	0.2%
Tax Expense	(202)	(405)	(285)	41.1%	(278)	2.7%
Minority Interest	0	(2)	(2)	481.9%	0	481.9%
Net Profit After Tax, pre Exceptionals	1,347	1,707	1,681	24.8%	1,687	(0.4%)
Exceptional gain/(loss)	22	137	(45)	(305.2%)		NA
Net Profit After Tax	1,369	1,844	1,636	19.5%	1,687	(3.0%)
NPM, pre exceptional	22.9%	24.5%	25.2%		25.1%	
Key operating statistics						
Sales (HKD m)						
Automobile glass products	1,990	1,758	1,871	(6.0%)	1,863	0.4%
Construction glass	1,220	1,370	1,186	(2.7%)	1,147	3.4%
Float glass	2,675	3,835	3,619	35.3%	3,708	(2.4%)
Total	5,885	6,963	6,677	13.5%	6,718	(0.6%)
Gross profit (HKD m)						
Automobile glass products	969	867	894	(7.7%)	912	(1.9%)
Construction glass	476	556	445	(6.6%)	438	1.6%
Float glass	596	1,195	1,090	82.9%	1,125	(3.1%)
Total	2,041	2,618	2,429	19.0%	2,474	(1.8%)
Gross margin						
Automobile glass products	48.7%	49.3%	47.8%	-0.9 ppt	48.9%	-1.1 ppt
Construction glass	39.0%	40.6%	37.5%	-1.5 ppt	38.1%	-0.7 ppt
Float glass	22.3%	31.2%	30.1%	7.8 ppt	30.3%	-0.2 ppt
Overall	34.7%	37.6%	36.4%	1.7 ppt	36.8%	-0.5 ppt

Source: Company, CLSA



Still expecting stable float glass demand/supply, with lower costs/Malaysia to help GPM in 2H17

## Stable float glass, expecting better 2H

We reiterate our view of stable demand/supply dynamics for float glass in 2017. The YTD property sales value, sales GFA and new starts GFA growth stayed positive at 21.5%, 16.1% and 10.6%, respectively, despite tightening policies, and we expect property sales to continuously be supported by lower-tier cities where inventory remains relatively low. We also see a more constructive 2H17, with seasonally stronger demand to provide support to prices, and the fall in soda ash/natural gas prices at end-1Q17 to contribute in full in 2H17.

The  $1^{st}$  production line in Malaysia (900t/d) commenced operation in 2Q17. Management estimates its GPM to be 10ppt+ higher than that for China currently. This will also help margin in 2H. The two other production lines (1,200t/d and 800t/d) in Malaysia will commence operation in 2H18.



Source: WIND, CLSA



Float glass prices stayed at high level

YTD Property sales/new starts have started to slow but not yet massively



Source: NBS, CLSA

Float glass capacity under operation in China (including lines just ignited and ultra-clear lines)



Figure 5

Glass demand lags behind property sales



Source: NBS, CLSA

Figure 7

#### Domestic soda ash prices





#### New expansion plans

Given the favourable float glass performance globally, management is planning to increase its float glass capacity by 50% from the 2017 level, with no limitation on geographical location. In addition to the new 2,000t/d capacity in Malaysia under construction, this could imply another c.6,000t/d capacity. Besides, XYG is also planning to add auto glass capacity – its current OEM glass capacity is c.2% of global and management's target is ~6%. For the aftermarket, XYG will also set up a new overseas capacity to reduce the impact of anti-dumping by other countries. We have not yet included these expansion plans in our forecasts, but these are likely positive earnings drivers; especially, overseas float glass plants, say in the US and Malaysia, would bring cost advantages.

Source: WIND, CLSA

Still expecting stable float glass demand/supply, with lower cost/Malaysia to help GPM in 2H17

Figure 6



Source: Company, CLSA

#### Figure 10







#### Fine-tuning forecasts

## Maintain BUY

We fine-tune our 17/18/19CL core profit forecasts by -0.4%/-0.8%/-0.2% to factor in slightly higher revenue offset by slightly lower GPM. We also factor in lower opex and higher associate income offset by lower other income and higher interest. Our TP is unchanged at HK\$9.60, based on a blended PE/PB approach: for PE, we apply 10x avg 18-19CL EPS; for PB we use a target multiple of 2.0x on avg 17-18CL BVPS. Retain BUY on an undemanding valuation of 8x 18CL PE/6% dividend yield potential, with stabilising float glass demand/supply dynamics (eg less worry on property sector, supply limitation amid pollution controls), cost reduction (eg, natural gas) and more capacity expansion details as potential key catalysts.



Source: Company, CLSA



Figure 9



Earnings	revisions

		17CL			18CL	
	New	Old	Change	New	Old	Change
Revenue (HK\$ m)	14,336	14,278	0.4%	15,292	15,228	0.4%
- Automobile glass products	3,806	3,806	0.0%	3,879	3,879	0.0%
- Construction glass	2,638	2,638	0.0%	2,722	2,722	0.0%
- Float glass (inc. electronic glass)	7,873	7,815	0.7%	8,616	8,552	0.8%
- Wind farm	19	19	0.0%	75	75	0.0%
Gross profit margin	37.7%	<b>38.0</b> %	-0.4 ppt	38.6%	38.9%	-0.3 ppt
- Automobile glass products	49.3%	50.2%	-0.9 ppt	50.6%	51.2%	-0.6 ppt
- Construction glass	39.0%	39.4%	-0.4 ppt	38.4%	38.8%	-0.4 ppt
- Float glass (inc. electronic glass)	31.6%	31.6%	-0.1 ppt	33.1%	33.2%	-0.1 ppt
- Wind farm	70.3%	70.3%	0.0 ppt	70.3%	70.3%	0.0 ppt
Core profit (HK\$ m)	3,745	3,760	-0.4%	4,161	4,195	-0.8%

Our TP is based on a blended PE and PB approach, with higher multiples amid market rerating

**Current market-cap** implies 8.7x/7.7x its nonsolar businesses earnings in 17/18CL

Valuation of Xinyi Glass	
PE basis	
Average 18-19CL EPS (HK\$)	1.10
Target multiple (x)	10.0
Fair value (HK\$)	11.00
PB basis	
Average 17-18CL BVPS (HK\$)	4.06
Target multiple (x)	2.0
Fair value (HK\$)	8.10
Average (HK\$)	9.60
Implying 17/18CL PE	10.2x/9.3x
Source: CLSA	

Valuation of Xinyi Glass's non-solar busin	ess		
HK\$m		FY17CL	FY18CL
Net profit of Xinyi Glass		3,745	4,161
Less: after-tax share of profits of Xinyi Solar		(635)	(644)
Non-solar profit	(a)	3,109	3,516
Current market cap of Xinyi Glass	(b)	32,315	32,315
Current market cap of Xinyi Solar	(c)	18,262	18,262
M'cap of Xinyi Glass's non-solar business	(d) = (b) - 29.5%*(c)	26,922	26,922
PE of Xinyi Glass's non-solar business	(e) = (d)/(a)	8.7	7.7
Source: CLSA			





Source: CLSA, Datastream



Source: CLSA, Datastream

Valuation comp – X	inyi Glas	s																	
Stock	Ticker	Price (local)	Mkt Cap (USD,m)		Rec	CLSA Target	Uncido	PE	12m for PB		luations EV/Ebitda	DOF	EPS Cagr FY1-FY3	PEG	Gearing (%)	Per 1m	rforma		(%) 12m
Xinyi Glass	868 HK	(IOCAI) 8.08	4,137	8.9	BUY	9.60	19%	8.1	2.0	6.0	7.3	26.0	10.9	0.7	37	5	21	19	44
Fuyao Glass - H	3606 HK	26.65	8,646	7.4	BUY	32.60	22%	15.0	2.8	4.0	9.6	19.8	17.2	0.9	0	(11)	(3)	16	36
China Glass	3300 HK	0.72	167	0.1											55	3	(17)	(14)	(30)
Luoyang Glass	1108 HK	4.31	881	0.8											106	(0)	(15)	(17)	(0)
CSG Holding	000012 CH	8.63	2,488	17.6				21.0							73	6	(0)	(13)	(8)
Fuyao Glass - A	600660 CH	23.25	8,646	56.8				15.6					14.4	1.1	0	(11)	3	24	42
Yaohua Pilkington	600819 CH	7.22	931	6.5											48	7	(1)	(12)	2
Shandong Jinjing	600586 CH	5.70	1,236	10.4											57	17	12	24	33
AVIC Sanxin	002163 CH	7.83	935	10.3											287	(5)	(7)	(16)	12
Xiuqiang Glasswork	300160 CH	8.88	789	12.5				23.2	3.1	0.6	14.5	14.5	16.4	1.4	11	(1)	(6)	(22)	(25)
Changzhou Almaden	002623 CH	24.29	578	6.9				27.5							39	(10)	(17)	(34)	(27)
Zhuzhou Kibing	601636 CH	5.37	2,142	26.6				12.3	1.8	3.9	7.9	15.7	16.7	0.7	56	19	24	28	68
Taiwan Glass	1802 TT	15.45	1,486	1.5											44	5	0	17	15
Asahi Glass	5201 JP	4,650.00	9,889	39.0	O-PF	5,150.00	11%	79.9	4.9	0.5	22.0	6.2	(0.9)		25	(2)	(4)	11	56
Nippon Sheet Glass	5202 JP	935.00	764	10.3				9.9					37.1	0.3	233	1	8	1	23
Central Glass	4044 JP	485.00	942	3.2				10.7					9.9	1.1	24	0	1	(11)	9
Hankuk Glass Industries	002000 KS	30,900.00	278	0.5											(21)	(0)	18	15	14
Cie de St-Gobain	SGO FP	47.31	31,098	109.2				14.7					13.9	1.1	29	1	(5)	4	25
PPG Industries Inc	PPG US	106.35	27,277	134.8				16.3	5.3	1.7	10.9		10.8	1.5	52	(3)	(3)	6	2
Turkiye Sise	SISE TI	4.51	2,874	5.7				11.1					10.6	1.1	13	8	11	23	47
Trakya Cam Sanayii	TRKCM TI	3.73	1,194	2.5				11.0					9.9	1.1	32	17	32	47	85
Corning	GLW US	29.52	26,653	191.5				16.4	1.7	2.3	8.7	10.5	9.1	1.8	(8)	(2)	2	11	33
Average								19.5	3.1	2.7	11.6	15.4	13.5	1.1	54.2				

Source: Bloomberg (for the not-rated stocks), CLSA (for the rest)

## Valuation details

We value XYG using a blended PE and PB approach. We apply a target multiple of 10x to avg 18-19CL EPS and a target multiple of 2.0x to avg 17-18CL BVPS, in line with the historical averages.

#### **Investment risks**

Key risks include: 1) Weakening of the property market or even the auto market. Demand for float glass and construction glass is highly dependent on the property market. Besides, despite being a stable business, the auto glass segment is correlated to the global number of vehicles in use, and any significant slowdown in the global auto industry may also affect the segment's performance. 2) Further tightening of credit. Tightening of credit also affects developers' cash flows and progress in construction of property projects. 3) Incremental production costs. A significant surge in natural gas, international crude oil prices and other raw material costs may affect XYG's gross margin if it cannot pass on incremental costs by raising ASP. 4) More capacity additions in the market.

## Valuation details - Asahi Glass Co Ltd 5201 JP

We value the stock using a PE valuation methodology as the company's earnings trends have brightened as chemicals and flat glass earnings growth offsets LCD weakness. We forecast Asahi Glass to see revenue and operating profit growth in the medium term as the US and Eurozone economies improve and chemicals experience success with new products along with growth in Southeast Asia.



## Investment risks - Asahi Glass Co Ltd 5201 JP

Fluctuating fuel costs are a risk because almost all of its businesses consume large amounts of fuel and materials. A US\$1 fall in oil prices adds ¥400m to OP. An increase in oil prices would cause a decline in profits. We expect the LCD substrate market to continue to see price cuts, but if weakness in downstream markets put more pressure on prices they may decline more than our expectations. The company is expecting ¥30bn in non-operating costs, but we are assuming ¥20bn. If non-operating costs reach ¥30bn, net profits would drop which would affect our PB-ROE correlation derived PB multiple.

## Valuation details - Fuyao Glass Industry Group Co Ltd 3606 HK

We use PE valuation as our primary valuation tool for Fuyao in order to capture the earnings growth momentum. We use DCF model as a cross-check, given the strong cash flow of the company to provide steady dividend payments.

## Investment risks - Fuyao Glass Industry Group Co Ltd 3606 HK

Key risks include: 1) slowdown of the Chinese and global auto industry affecting product demand; 2) increasing competition in the market, mainly from existing players largely accelerating their capacity additions; 3) increasing costs of raw material, especially those used to manufacture float glass such as fuel (eg natural gas) and soda ash; 4) slower-than-expected ramp-up of the new production facilities, especially those located overseas, and lower-than-expected profitability of these new plants; 5) unfavourable currency movements, like RMB appreciation; and 6) political risk arising from increasing overseas exposure.





## **Summary financials**

	Summary m					
	Year to 31 December	2015A	2016A	2017CL	2018CL	2019CL
	Summary P&L forecast (Hk	(\$m)				
	Revenue	11,460	12,848	14,336	15,292	16,060
	Op Ebitda	2,313	3,664	4,343	4,932	5,358
Steady earnings growth	Op Ebit	1,518	2,837	3,464	3,950	4,309
ahead	Interest income	40	51	70	51	31
alleau	Interest expense	(90)	(128)	(131)	(128)	(73)
	Other items	912	1,063	993	1,022	1,190
	Profit before tax	2,380	3,823	4,397	4,895	5,457
	Taxation	(266)	(607)	(649)	(732)	(801)
	Minorities/Pref divs	0	(3)	(3)	(3)	(3)
	Net profit	2,113	3,213	3,745	4,161	4,653
	Summary cashflow forecast	: (HK\$m)				
	Operating profit	1,518	2,837	3,464	3,950	4,309
	Operating adjustments	-	-	-	-	-
	Depreciation/amortisation	795	827	879	982	1,050
	Working capital changes	(207)	(426)	(201)	(104)	(84)
	Net interest/taxes/other	(421)	(784)	(780)	(860)	(874)
Concernation in the last of	Net operating cashflow	1,685	2,453	3,362	3,968	4,400
Capex mainly on Malaysia	Capital expenditure	(1,967)	(1,853)	(3,000)	(1,500)	(1,500)
investments and Qianhai	Free cashflow	(282)	600	362	2,468	2,900
land	Acq/inv/disposals	-	-	-	-	-
	Int, invt & associate div	951	1,112	1,061	1,070	1,218
	Net investing cashflow	(1,016)	(741)	(1,939)	(430)	(282)
	Increase in loans	16	1,646	933	(3,171)	(1,808)
	Dividends	(1,029)	(1,622)	(1,810)	(2,011)	(2,249)
	Net equity raised/other	812	(267)	(446)	0	-
	Net financing cashflow	(202)	(244)	(1,324)	(5,182)	(4,057)
	Incr/(decr) in net cash	468	1,468	99	(1,644)	61
	Exch rate movements	-	-	-	-	-
	Opening cash	832	1,300	2,768	2,867	1,223
	Closing cash	1,300	2,768	2,867	1,223	1,285
	Summary balance sheet for	ecast (HK\$m)				
Balance sheet still healthy	Summary balance sheet for Cash & equivalents	ecast (HK\$m) 1,300	2,768	2,867	1,223	1,285
Balance sheet still healthy				2,867 1,212	1,223 1,293	1,285 1,358
Balance sheet still healthy	Cash & equivalents	1,300	2,768			
Balance sheet still healthy	Cash & equivalents Debtors	1,300 1,136	2,768 1,036	1,212	1,293	1,358
Balance sheet still healthy	Cash & equivalents Debtors Inventories	1,300 1,136 1,223 1,337 11,971	2,768 1,036 1,321	1,212 1,396	1,293 1,454	1,358 1,502
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets	1,300 1,136 1,223 1,337	2,768 1,036 1,321 1,412	1,212 1,396 1,858	1,293 1,454 1,858	1,358 1,502 1,858
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets	1,300 1,136 1,223 1,337 11,971 1,281 3,174	2,768 1,036 1,321 1,412 11,831	1,212 1,396 1,858 14,009 1,136 4,462	1,293 1,454 1,858 14,581 1,082 4,462	1,358 1,502 1,858 15,083 1,030 4,462
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b>	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b>	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b>	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b>	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b>	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b>
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 266	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66
Balance sheet still healthy	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669
Balance sheet still healthy Decent ROE	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b>	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669
-	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b>	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b>	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b>	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b>	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b>	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b>
-	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b>	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 111.6	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b>	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0
-	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda growth (% YoY)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b>	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 11.6 18.5	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b> 6.7 13.6	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0 8.7
-	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets Total assets Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda growth (% YoY)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b> 12.1 58.4 28.5	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 111.6 18.5 30.3	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b> 6.7 13.6 32.3 2,7.2 48.5	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0 8.7 33.4
-	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b> 12.1 58.4 28.5 25.0	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 111.6 18.5 30.3 26.1	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b> 6.7 13.6 32.3 2,7.2	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0 8.7 33.4 29.0
	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b> 12,1 58,4 28,5 25,0 49,7	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 11.6 18.5 30.3 26.1 48.0	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b> 6.7 13.6 32.3 27.2 48.5 15.0 64.2	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0 8.7 33.4 29.0 48.5 14.7 128.2
	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b> 12.1 58.4 28.5 25.0 49.7 15.9	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 11.6 18.5 30.3 26.1 48.0 14.8	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b> 6.7 13.6 32.3 27.2 48.5 15.0	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0 8.7 33.4 29.0 48.5 14.7
	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%) Ebitda/net int exp (x)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b> 12.1 58.4 28.5 25.0 49.7 15.9 47.7	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 11.6 18.5 30.3 26.1 48.0 14.8 71.9	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b> 6.7 13.6 32.3 27.2 48.5 15.0 64.2	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0 8.7 33.4 29.0 48.5 14.7 128.2
	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%) Ebitda/net int exp (x) Net debt/equity (%)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b> 12.1 58.4 28.5 25.0 49.7 15.9 47.7 37.0	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 11.6 18.5 30.3 26.1 48.0 14.8 71.9 37.8 26.5 17.8	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b> 6.7 13.6 32.3 27.2 48.5 15.0 64.2 24.3	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0 8.7 33.4 29,0 48.5 14.7 128.2 11.9
	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%) Ebitda/net int exp (x) Net debt/equity (%) ROE (%)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2 16.9	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b> 12.1 58.4 28.5 25.0 49.7 15.9 47.7 37.0 24.8	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 11.6 18.5 30.3 26.1 48.0 14.8 71.9 37.8 26.5	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b> 6.7 13.6 32.3 27.2 48.5 15.0 64.2 24.3 25.7	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0 8.7 33.4 29,0 48.5 14.7 128.2 11.9 25.2
	Cash & equivalents Debtors Inventories Other current assets Fixed assets Intangible assets Other term assets <b>Total assets</b> Short-term debt Creditors Other current liabs Long-term debt/CBs Provisions/other LT liabs Minorities/other equity Shareholder funds <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda growth (% YoY) Ebitda margin (%) Net profit margin (%) Dividend payout (%) Effective tax rate (%) Ebitda/net int exp (x) Net debt/equity (%) ROE (%) ROIC (%)	1,300 1,136 1,223 1,337 11,971 1,281 3,174 <b>21,422</b> 2,514 740 1,705 3,514 223 7 12,718 <b>21,422</b> 5.5 33.0 20.2 18.4 50.5 11.2 46.1 37.2 16.9 8.7	2,768 1,036 1,321 1,412 11,831 1,193 4,462 <b>24,022</b> 3,165 789 2,046 4,509 2,66 66 13,181 <b>24,022</b> 12.1 58.4 28.5 25.0 49.7 15.9 47.7 37.0 24.8 15.7	1,212 1,396 1,858 14,009 1,136 4,462 <b>26,940</b> 3,550 839 2,046 5,057 266 66 15,115 <b>26,940</b> 11.6 18.5 30.3 26.1 48.0 14.8 71.9 37.8 26.5 17.8	1,293 1,454 1,858 14,581 1,082 4,462 <b>25,954</b> 2,242 875 2,046 3,194 266 66 17,265 <b>25,954</b> 6.7 13.6 32.3 27.2 48.5 15.0 64.2 24.3 25.7 18.4	1,358 1,502 1,858 15,083 1,030 4,462 <b>26,578</b> 1,497 903 2,046 2,132 266 66 19,669 <b>26,578</b> 5.0 8.7 33.4 29,0 48.5 14.7 128.2 11.9 25.2 19,5





#### **Research subscriptions**

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email\_alert/.

## **Companies mentioned**

Xinyi Glass (868 HK - HK\$8.08 - BUY) Asahi Glass (5201 JP - ¥4,650 - O-PF) AVIC Sanxin (N-R) Central Glass (N-R) Changzhou Almaden (N-R) China Glass (N-R) Cie de St-Gobain (N-R) Corning (N-R) CSG - A (N-R) Fuyao Glass - A (600660 CH - RMB23.24 - BUY) Fuyao Glass (3606 HK - HK\$26.65 - BUY) Hankuk Glass Industries (N-R) Jinjing (N-R) Kibing (N-R) Luoyang Glass (N-R) NSG (N-R) PPG (N-R) Sise Cam (N-R) SYP Glass - A (N-R) Taiwan Glass (N-R) Trakya Cam Sanayii (N-R) Xinyi Solar (968 HK - HK\$2.46 - BUY) Xiuqiang Glasswork (N-R)

## **Analyst certification**

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.



## Important disclosures



Date	Rec	rarget	Date	Nee	rarget
17 Jul 2017	BUY	9.60	05 Feb 2016	O-PF	4.24*
14 Dec 2016	BUY	8.35	19 Nov 2015	O-PF	4.33*
08 Nov 2016	BUY	8.30	29 Jul 2015	O-PF	4.24*
08 Sep 2016	BUY	8.35	24 Apr 2015	O-PF	4.90*
03 Aug 2016	BUY	7.25	03 Mar 2015	O-PF	4.81*
15 Jun 2016	O-PF	6.12*	10 Dec 2014	O-PF	4.23*
04 May 2016	O-PF	5.56*	25 Sep 2014	O-PF	5.28*
16 Mar 2016	O-PF	4.80*			

Source: CLSA; \* Adjusted for corporate action

#### Recommendation history of Asahi Glass Co Ltd 5201 JP



Source: CLSA; \* Adjusted for corporate action



Source: CLSA

#### Recommendation history of Xinyi Solar Holdings Ltd 968 HK



Date	Rec	Target	Date	Rec	Target
01 Aug 2017	BUY	3.10	19 Nov 2015	BUY	4.67*
17 Jul 2017	BUY	3.00	02 Nov 2015	BUY	4.57*
22 Apr 2017	BUY	2.98*	19 Oct 2015	BUY	4.67*
28 Feb 2017	BUY	3.38*	12 Jun 2015	BUY	4.55*
14 Dec 2016	BUY	3.48*	27 May 2015	BUY	4.07*
18 Oct 2016	BUY	3.87*	24 Apr 2015	BUY	3.56*
15 Jun 2016	BUY	4.17*	12 Mar 2015	BUY	3.11*
16 Mar 2016	BUY	3.97*	04 Dec 2014	BUY	3.25*
05 Feb 2016	BUY	4.07*	25 Sep 2014	BUY	3.18*
12 Jan 2016	BUY	4.57*			

Source: CLSA; \* Adjusted for corporate action

The policy of CLSA (which for the purpose of this disclosure includes its subsidiary CLSA B.V.) and CL Securities Taiwan Co., Ltd. ("CLST") is to only publish research that is impartial, independent, clear, fair, and not misleading. Analysts may not receive compensation

from the companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out at www.clsa.com/disclaimer.html and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of a discloseable position should not be taken as endorsement on the validity or quality of the research report or recommendation.

To maintain the independence and integrity of CLSA's research, our Corporate Finance, Sales Trading and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA Corporate Finance (or "investment banking") department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management.

CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading and Research activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a preexisting holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

Unless specified otherwise, CLSA/CLST did not receive investment banking/non-investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, CLSA/CLST does not own a material discloseable position, and does not make a market, in the securities.

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, nonpublic information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF: Total expected return below 20% but exceeding market return; U-PF: Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the stock against the stock trades.

We define as "Double Baggers" stocks we expect to yield 100% or more (including dividends) within three years at the time the stocks are introduced to our "Double Bagger" list. "High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA/CLST only Universe:

Overall rating distribution: BUY / Outperform - CLSA: 64.52%; CLST only: 67.61%, Underperform / SELL - CLSA: 35.48%; CLST only: 32.39%, Restricted - CLSA: 0.00%; CLST only: 0.00%. Data as of 30 June 2017.

Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 4.77%; CLST only: 0.00%, Underperform / SELL - CLSA: 2.98%; CLST only: 0.00%, Restricted - CLSA: 0.00%; CLST only: 0.00%. Data for 12-month period ending 30 June 2017. There are no numbers for Hold/Neutral as CLSA/CLST do not have such investment rankings.

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: (a) CLSA, Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; (b) CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). © 2017 CLSA Limited and/or CLST.

© 2017 CLSA Limited, and/or CL Securities Taiwan Co., Ltd. ("CLST")

This publication/communication is subject to and incorporates the terms and conditions of use set out on the www.clsa.com website (www.clsa.com/disclaimer.html.). the Neither publication/communication nor any portion hereof may he reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA group of companies ("CLSA") and/or CLST.

**CLSA** and/or CLST have produced this publication/communication for private circulation to professional, institutional and/or wholesale clients only. This publication/communication may not be distributed or redistributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. This is not a solicitation or any offer to buy or sell. This publication/communication is for information does purposes only and not constitute anv recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk

factors. This is not intended to provide professional, any other investment or type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates or companies or individuals connected with CLSA /CLST may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that CLSA, CLST and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the discloseable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at http://www.clsa.com/member/research\_disclosures/.

Disclosures therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company covered in this publication/communication. If investors have any difficulty accessing this website, please contact webadmin@clsa.com on +852 2600 8111. If you require disclosure information on previous dates, please contact compliance\_hk@clsa.com.

This publication/communication is distributed for and on behalf of CLSA Limited (for research compiled by nonUS and non-Taiwan analyst(s)), and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd; in Hong Kong by CLSA Limited; in India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; SEBI Registration No: INZ000001735; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd; in Korea by CLSA Securities Korea Ltd; in Malaysia by CLSA Securities Malaysia Sdn Bhd; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST and in the United Kingdom by CLSA (UK).

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No.INM000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking securities and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com.

United States of America: Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

Canada: The delivery of this research report to any person in Canada shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in Canada wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

United Kingdom: In the United Kingdom, this research is a marketing communication. It has not been prepared

in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The research is disseminated in the EU by CLSA (UK), which is authorised and regulated by the Financial Conduct Authority. This document is directed at persons having professional experience in matters relating to investments as defined in Article 19 of the FSMA 2000 (Financial Promotion) Order 2005. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where the research material is compiled by the UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules this research is prepared and intended as substantive research material.

Singapore: In Singapore, research is issued and/or distributed by CLSA Singapore Pte Ltd (Company Registration No.: 198703750W), a Capital Markets Services licence holder to deal in securities and an exempt financial adviser, solely to persons who qualify as an institutional investor, accredited investor or expert investor, as defined in s.4A(1) of the Securities and Futures Act. Pursuant to Paragraphs 33, 34, 35 and 36 of the Financial Advisers (Amendment) Regulations 2005 of the Financial Advisers Act (Cap 110) with regards to an institutional investor, accredited investor, expert investor or Overseas Investor, sections 25, 27 and 36 of the Financial Adviser Act (Cap 110) shall not apply to CLSA Singapore Pte Ltd. Please contact CLSA Singapore Pte Ltd (telephone No.: +65 6416 7888) in connection with queries on the report. MCI (P) 033/11/2016

The analysts/contributors to this publication/communication may be employed by any relevant CLSA entity, CLST or a subsidiary of CITIC Securities Company Limited which is different from the entity that distributes the publication/communication in the respective jurisdictions.

MSCI-sourced information is the exclusive property of Morgan Stanley Capital International Inc (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular



purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are service marks of MSCI and its affiliates. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor's. GICS is a service mark of MSCI and S&P and has been licensed for use by CLSA.

 ${\rm EVA} \circledast$  is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA and "CT" stands for CLST estimates unless otherwise noted in the source.